New Medications to Combat The Terrible Symptoms of Scleroderma
This Petition was created because of the way pharmaceutical companies are making decisions concerning medications for rare diseases. They first consider whether or not the new medications for rare diseases are profitable; instead of considering how badly the medications are needed by those who have rare diseases.
Pharmaceutical companies are also profiting excessively by setting very high prices for treatment for rare diseases.
Following is an excerpt from:
HEALTH INC.
DRUGS FOR RARE DISEASES HAVE BECOME UNCOMMONLY RICH MONOPOLIES
Jan. 17, 2017 4:59 p.m.
More than 30 years ago, Congress overwhelmingly passed a landmark health bill aimed at motivating pharmaceutical companies to develop new drugs for people whose rare diseases had been ignored. By the drug makers' calculations, the markets for such diseases weren't big enough to bother with.
But lucrative financial incentives created by the Orphan Drug Act signed into law by President Reagan in 1983 succeeded far beyond anyone's expectations. More than 200 companies have brought almost 450 so-called orphan drugs to market since the law took effect.
Read our second orphan drug story
Shots - Health News
High Prices For Orphan Drugs Strain Families And Insurers
Yet a Kaiser Health News investigation shows that the system intended to help desperate patients is being manipulated by drug makers to maximize profits and to protect niche markets for medicines already being taken by millions. The companies aren't breaking the law but they are using the Orphan Drug Act to their advantage in ways that its architects say they didn't foresee or intend. Today, many orphan medicines, originally developed to treat diseases affecting fewer than 200,000 people, come with astronomical price tags."
Please take action to stop this in justice.
Pharmaceutical companies are also profiting excessively by setting very high prices for treatment for rare diseases.
Following is an excerpt from:
HEALTH INC.
DRUGS FOR RARE DISEASES HAVE BECOME UNCOMMONLY RICH MONOPOLIES
Jan. 17, 2017 4:59 p.m.
More than 30 years ago, Congress overwhelmingly passed a landmark health bill aimed at motivating pharmaceutical companies to develop new drugs for people whose rare diseases had been ignored. By the drug makers' calculations, the markets for such diseases weren't big enough to bother with.
But lucrative financial incentives created by the Orphan Drug Act signed into law by President Reagan in 1983 succeeded far beyond anyone's expectations. More than 200 companies have brought almost 450 so-called orphan drugs to market since the law took effect.
Read our second orphan drug story
Shots - Health News
High Prices For Orphan Drugs Strain Families And Insurers
Yet a Kaiser Health News investigation shows that the system intended to help desperate patients is being manipulated by drug makers to maximize profits and to protect niche markets for medicines already being taken by millions. The companies aren't breaking the law but they are using the Orphan Drug Act to their advantage in ways that its architects say they didn't foresee or intend. Today, many orphan medicines, originally developed to treat diseases affecting fewer than 200,000 people, come with astronomical price tags."
Please take action to stop this in justice.
View Comments